Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitotic kinesin Eg5, also known as Kinesin-5, KSP, or KIF11, is a member of the kinesin superfamily involved in spindle formation and maintenance during mitosis. As a homotetrameric bipolar motor protein, it crosslinks and slides apart anti-parallel microtubules, driving centrosome separation and maintaining spindle bipolarity. Eg5 moves toward the plus ends of microtubules using ATP hydrolysis. It is a validated target for antimitotic cancer therapies, and small-molecule inhibitors block its function, leading to mitotic arrest. Outside of cell division, Eg5 is involved in axonal growth regulation and may serve as a mobile link between ribosomes and microtubules.
Inhibition of Eg5 ATPase activity, leading to mitotic arrest and apoptosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitotic kinesin Eg5 (Eg5).